Chapter 32 — Further Reading

How Peptides Are Made — Solid-Phase Synthesis, Recombinant Production, and Why Peptide Drugs Cost What They Cost

A note on how to use this list. Peptide manufacturing is unusual among this book's topics in that the primary literature is largely a process chemistry literature — written by and for people who make things at scale — while the popular literature is largely a history of biotechnology literature. Those two bodies of writing barely overlap, and reading only one of them produces a lopsided picture. Tier 1 mixes them deliberately.

None of the sources below is a protocol source, and none should be read as one. Several are technical reviews that describe reagents and conditions because that is what technical reviews do. This book's position is unchanged: understanding the chemistry is the goal; performing it is not.

Tier 1 — Start here

Merrifield, R. B. "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide." Journal of the American Chemical Society, 1963. The founding paper. It is four pages, it is readable by anyone who has finished Chapter 1, and it is worth reading precisely because of how modest it is. There is no rhetoric about transforming a field; there is a problem, an idea, and a tetrapeptide. Read it and then look at the date on any peptide drug label in your medicine cabinet.

Merrifield, R. B. Nobel Lecture, "Solid Phase Synthesis," 1984. (Freely available from the Nobel Foundation.) Merrifield describing his own work twenty years on, with the benefit of knowing what it became. Nobel lectures are a genuinely underused genre — they are the one place a scientist is licensed to explain motivation and false starts. Read this second, after the 1963 paper, so you can see which parts he thought mattered in hindsight.

Goeddel, D. V., et al. "Expression in Escherichia coli of chemically synthesized human insulin genes." Proceedings of the National Academy of Sciences USA, 1979. The recombinant insulin paper discussed in Case Study 32.1. Read it for the fusion-protein strategy and for what it does not claim — the paper is about expression, and the chain-combination step that became the industrial bottleneck is handled briskly. A good exercise in noticing where a paper's difficulty actually sits.

Hughes, Sally Smith. Genentech: The Beginnings of Biotech. University of Chicago Press, 2011. A historian's account of the company and the period, based on extensive oral histories. The most readable route into how the 1979–1982 insulin work actually happened, including the parts that were commercial and legal rather than scientific. It also does something rare: it takes seriously the question of what the scientists thought they were doing at the time.

Any current pharmacopeial monograph for a peptide drug substance — for instance a USP or European Pharmacopoeia monograph. (Often accessible through a university or hospital library.) This is an unusual recommendation and the most useful one on the list. Do not read it for content; read it for shape. Look at how many separate parameters are specified, how each test is named and referenced, and what the acceptance limits are. Then reread §32.4. After you have seen one monograph, the phrase "pharmaceutical grade" will never look the same again.

Tier 2 — Going deeper

Behrendt, R., White, P., and Offer, J. "Advances in Fmoc solid-phase peptide synthesis." Journal of Peptide Science, 2016. A well-organized review of where Fmoc chemistry actually stands, including honest treatment of difficult sequences, aggregation, and side reactions. Technical, but written with unusual clarity about why things are done rather than only what is done.

Isidro-Llobet, A., et al. "Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production." Journal of Organic Chemistry, 2019. The paper to read if §32.8's claim about solvent volumes surprised you. It quantifies the environmental footprint of peptide manufacture and surveys what is being done about it. It is also the best single antidote to the "peptides cost pennies to make" claim, because it makes the material inputs concrete.

Kent, S. B. H. "Total chemical synthesis of proteins." Chemical Society Reviews, 2009. On native chemical ligation and the extension of chemical synthesis into protein-sized territory. Read it as a direct engineering response to the §32.3 exponential — this is the field's answer to the question "what if we refuse to accept that limit?"

Baeshen, N. A., et al. "Cell factories for insulin production." Microbial Cell Factories, 2014. A survey of expression systems and process routes for recombinant insulin — bacterial versus yeast, inclusion bodies versus secretion, precursor design. The technical follow-through to Case Study 32.1.

Frederick, M. O., et al., and the broader process-chemistry literature on peptide manufacture at commercial scale. Rather than a single citation, this is a pointer to a genre. Search the process chemistry journals — Organic Process Research & Development above all — for the manufacturing routes of specific peptide drugs. These papers are written by people who had to make a tonne of something, and they are candid about what went wrong in a way that discovery-chemistry papers are not.

The FDA drug shortage database and the corresponding EMA shortage listings. (Public, free, searchable.) Not reading in the usual sense, but worth an hour. Look up a shortage — GLP-1 or otherwise — and read the stated reason. You will find that "manufacturing delay" and "capacity" are the dominant categories and that "active ingredient supply" is comparatively rare. §32.7 in raw form.

Tier 3 — For the committed

Chan, W. C., and White, P. D. (eds.) Fmoc Solid Phase Peptide Synthesis: A Practical Approach. Oxford University Press. The standard laboratory reference. Listed here for completeness and for readers who want to see how comprehensively the difficulties have been cataloged — the chapters on side reactions and on difficult sequences are an education in how much of chemistry is failure management. It is a protocol book. This textbook's position on protocols has not changed.

Ph. Eur. and USP general chapters on peptide characterization, amino acid analysis, and residual solvents. The methods behind §32.4's distinction between purity and content. Dry, and the only way to see exactly what a "validated method" commits a manufacturer to.

ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) and ICH Q3A/Q3B (Impurities in New Drug Substances and Products). The regulatory framework behind the phrase "manufactured under GMP to a monograph." Q3A in particular is the document that formalizes the distinction between total impurities and individual impurities that Case Study 32.2 turns on.

Vigneaud, V. du. Nobel Lecture, 1955, and the associated oxytocin synthesis papers. The state of the art immediately before Merrifield. Reading these and then the 1963 paper back to back gives you the discontinuity in a way no summary can.

Kinch, M. S., and related literature on pharmaceutical development attrition rates. For the "recovered development cost including failed programs" line in §32.8. If you want to argue about drug pricing seriously — in either direction — you need a defensible number for how many programs fail, and this is where to get one.

If you only do one thing

Find a pharmacopeial monograph for any peptide drug substance, and a certificate of analysis for any research-chemical peptide, and put them side by side.

Do not try to understand either document in detail. Just count.

Count how many distinct parameters the monograph specifies, and how many the certificate reports. Notice which categories appear in one and not the other — identity by a named method, individual impurity limits, water content, residual solvents, counterion, peptide content, endotoxin. Notice whether the certificate names the analytical method it used. Notice whether either document tells you who is accountable if it is wrong.

Ten minutes with those two documents will teach you more about §32.4 and §32.9 than any amount of rereading, because the difference is not an argument. It is a visible difference in the number of things somebody committed to.